

CÔNG TY CP DƯỢC HẬU GIANG
DHG PHARMACEUTICAL JSC.

Số/ No.: 459/DHG-FN

CỘNG HÒA XÃ HỘI CHỦ NGHĨA VIỆT NAM
Độc lập – Tự do – Hạnh phúc
THE SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

Cần Thơ, ngày 29 tháng 06 năm 2023
Cantho, 29th June 2023

CÔNG BỐ THÔNG TIN BẤT THƯỜNG
EXTRAORDINARY INFORMATION DISCLOSURE

Kính gửi/ *Kind Attn to:* Ủy Ban Chứng Khoán Nhà Nước/ *State Securities Commission*
Sở Giao Dịch Chứng Khoán Tp. HCM/ *Ho Chi Minh Stock Exchange*

- Tên tổ chức/ *Name of organization:* Công ty Cổ phần Dược Hậu Giang/ *DHG Pharmaceutical JSC*
 - Mã chứng khoán/ *Ticker symbol:* DHG
 - Địa chỉ/ *Address:* 288 Bis Nguyễn Văn Cừ, P. An Hòa, Q. Ninh Kiều, Tp. Cần Thơ
288 Bis Nguyen Van Cu, An Hoa Ward, Ninh Kieu District, Cantho City
 - Điện thoại liên hệ/ *Tel:* 0292 3891 433 Fax: 0292 3895 209
 - E-mail: dhgpharma@dhgpharma.com.vn

2. Nội dung thông tin công bố/ *Contents of disclosure:*

Công ty Cổ phần Dược Hậu Giang (DHG Pharma) xin công bố Quyết định Hội đồng Quản trị (HĐQT) số 012/2023/QĐ.HĐQT ngày 29/06/2023 về việc phê duyệt giao dịch, hợp đồng giữa Công ty Cổ phần Dược Hậu Giang với tổ chức có liên quan Công ty Cổ phần Chế Tạo Thuốc Taisho liên quan đến các sản phẩm BFM (Quyết định HĐQT đính kèm).

DHG Pharma would like to disclose the Decision of the Board of Directors (BOD) No. 012/2023/QD.HDQT dated 29 June 2023 on approval of the transactions, contracts between DHG Pharmaceutical JSC and related party Taisho Pharmaceutical Co., Ltd. related to BFM products (BOD Decision has been enclosed).



3. Thông tin này đã được công bố trên trang thông tin điện tử của công ty vào ngày 29/06/2023 tại đường dẫn www.dhgpharma.com.vn
This information was published on the Company's website on the 29th of June, 2023, as in the link www.dhgpharma.com.vn

Chúng tôi xin cam kết các thông tin công bố trên đây là đúng sự thật và hoàn toàn chịu trách nhiệm trước pháp luật về nội dung các thông tin đã công bố.

We hereby certify that the information provided is true and correct and we bear the full responsibility to the law.

Nơi nhận/ Recipients:

- Như trên/ As above;
- Lưu/ Archived: AT, FN

TỔNG GIÁM ĐỐC/GENERAL DIRECTOR



Toshiyuki Ishii



DECISION

(Re: Approval of transactions, contracts between DHG Pharmaceutical JSC and related party Taisho Pharmaceutical Co., Ltd. related to BFM)

THE BOARD OF DIRECTORS OF DHG PHARMACEUTICAL JSC

- Pursuant to the Charter of DHG Pharmaceutical JSC (DHG Pharma) issued on 19 Apr 2021;
- Pursuant to Statement No.011/TTr.DHG-HĐQT dated 21 Jun 2023 of the General Director on the approval of transactions, contracts between DHG Pharmaceutical JSC and related party - Taisho Pharmaceutical Co., Ltd. related to BFM;
- Pursuant to Resolution No.009/2023/NQ.HĐQT dated 29 Jun 2023 of the BOD of DHG Pharma,

DECISION

Article 1: Approving the transactions, contracts between DHG Pharmaceutical JSC and related party - Taisho Pharmaceutical Co., Ltd. related to BFM with the following contents:

1. Partner: Taisho Pharmaceutical Co., Ltd. (Taisho)
2. Relationship: Taisho is the parent company of DHG Pharmaceutical JSC.
3. Transaction and contract contents: Sales and purchase of goods and services related to the import of BFM to Vietnamese market.

Article 2: The General Director is assigned to: (1) sign an addendum to the contract with Taisho to update the additional products of BFM and (2) continue to sign contract/addendum renewal for the brands approved by the BOD after the expiration of the contract dated 5 Oct 2021, with the condition:

- The total value of transactions, contracts with Taisho and its subsidiaries in the Taisho Group are guaranteed to be less than 25% of the total value of assets recorded in the latest financial statements of DHG Pharmaceutical JSC; and
- All transactions and contracts are ensured to comply with market principles, avoid conflicts of interests in accordance with the Charter, relevant regulations of DHG Pharmaceutical JSC and current laws; and
- The terms of the renewed contract/addendum should be equivalent to the terms of the previously signed contract/addendum.

Article 3: Members of the Board of Directors, Board of Management of DHG Pharma and relevant members, and units are responsible for the implementation of this decision.

This Decision takes effect from the date of signing./.

Recipients:

- As Article 3 “for implementation”;
- Archived: BOD Secretary.

OBO. THE BOARD OF DIRECTORS

CHAIRWOMAN

Dang Thi Thu Ha

[NOTICE: This Convocation Notice is a translation of the Vietnamese language original for convenience purpose only, and in the event of any discrepancy, the Vietnamese language original shall prevail.]